Histofy, an AI-driven leader in histopathology solutions, is excited to announce a new collaboration with Haukeland University Hospital (HUH), one of Norway’s premier medical institutions. The partnership aims to address a critical challenge in modern pathology: the classification of colon polyps. This initiative promises to improve efficiency, assisting pathologists in making quicker assessments for colorectal cancer prevention.
Bergen, Norway and Coventry, UK (14 October 2024) – Colon polyps are abnormal growths in the colon that, if left untreated, can develop into colorectal cancer, the second leading cause of cancer deaths worldwide. Efficient classification of these polyps is vital for determining the appropriate surveillance and treatment pathway and improving patient outcomes. Yet, the current classification process is time-consuming and heavily reliant on subjective interpretation, posing risks for misdiagnosis.
Through this collaboration, Histofy will lead the development of a cutting-edge AI tool using clinical data and expertise from HUH to classify colon polyps more efficiently. The groundbreaking technology will empower HUH’s pathology team, streamline workflows and deliver faster, more consistent results in the early detection of potential cancers. The Norwegian Colorectal Screening Program provides funding support for the project.
“This partnership represents a leap forward for pathology. By integrating AI into our diagnostic process, we anticipate not only more efficient workflows but also faster, more standardized diagnostics, which will ultimately benefit our patients,” said Professor Elisabeth Wik, the head of the pathology department at Haukeland University Hospital.
"We anticipate not only more efficient workflows but also faster, more standardized diagnostics, which will ultimately benefit our patients"
“We are thrilled to partner with Haukeland University Hospital, a recognised leader in clinical research and patient care,” said Professor David Snead, CMO of Histofy. “This collaboration aligns with our mission to harness AI to solve critical healthcare challenges and further proves the clinical value of AI in pathology.”
The project will focus on validating AI algorithms developed by Histofy and incorporating them into HUH’s diagnostic pipeline. This includes using AI to differentiate between various types of polyps and identify subtle features that might be overlooked by traditional methods. Ultimately, the collaboration will not only reduce diagnostic time but also improve treatment selection, surveillance plans and patient outcomes. Additionally, by reducing patient waiting time, it will help alleviate the sense of uncertainty, anxiety, and fear, as most polyps are truly benign.
About Histofy
Histofy is a cutting-edge medical AI startup specializing in pathology AI solutions. Their data-efficient transparent AI solutions ensure powerful performance with minimal data, making their solutions trustworthy and scalable for a wide range of healthcare settings.
About Haukeland University Hospital
Haukeland University Hospital is one of Norway’s largest hospitals and a leader in clinical innovation. Pathology diagnostics at HUH and across the entire Western Norway Health Region, including 3 additional pathology departments, is fully digitized providing a solid foundation for the implementation of AI tools. As a key medical center in Scandinavia, HUH is committed to advancing patient care through research, innovation, and collaboration.
For more information, please contact Dr Simon Graham at s.graham [at] histofy [dot] ai.
